PHT Corporation Publishes Pharmaceutical Industry’s First Free Tool for Choosing ePRO Modalities for Clinical Trial Manage

Global ePRO innovator makes it fast and easy to select optimal ePRO modality for collecting patient data during any clinical research phase

BOSTON and GENEVA, Switzerland--(BUSINESS WIRE)-- PHT Corporation continued its drive toward worldwide ePRO adoption today with the free publication of its popular ePRO Modality Tool. PHT is the global innovator in ePRO solutions that maximize the collection of high quality data from clinical trial patients.

Dozens of clinical trial managers within major pharmaceutical companies have used the PHT ePRO Modality Tool successfully to determine the right ePRO modality for specific trial types and phases. By publishing the Tool and lifting all previous restrictions for its use, PHT is blazing a new trail in promoting ePRO adoption.

PHT President and CEO Phil Lee said, “The time for ePRO is now. The ePRO Modality Tool makes it fast, easy and free for any pharmaceutical company to learn how and why ePRO is the best patient data collection method for ensuring a safe, economical, efficient clinical trial.”

PHT is uniquely qualified to launch the ePRO Modality Tool: It is the only ePRO vendor solely dedicated to ePRO, and the only company to offer a complete ePRO System with data collected via smartphone, tablet, Internet or handheld device.

Sheila Rocchio, PHT Vice President of Marketing, explained, “PHT has conducted more ePRO trials than our closest two competitors combined. We continue demonstrating our market dominance with unique content and context analyses derived from our unique global experiences with ePRO.”

Globally, there are five proven ways to collect ePRO data – smartphone, tablet, Internet, digital pen and hand held device. The PHT ePRO Modality Tool enables sponsors and CROs to determine which of the five methods is most effective for collecting ePRO data, based on their specific protocol. In the short amount of time it takes to answer three basic questions about their trial, users discover which collection method or methods are practical, and why. The questions are simple:

1) Where will the ePRO data be collected?

2) Will the PRO data be collected using simple or complex questionnaires and/or diaries?

3) Will PRO data be collected frequently scheduled, episodic or infrequently?

As the clinical trial professional answers each question, the PHT ePRO Modality Tool eliminates certain collection methods. The user can roll a mouse over the screen to read why a particular ePRO method is not suitable under their stated conditions, or what caveats may apply.

The PHT ePRO Modality Tool is freely available online, as an .exe file for PCs and for Blackberry, iPhone and Android Smartphones. To try the PHT ePRO Modality Tool, visit http://www.phtcorp.com/why_epro/epro/.

About PHT Corporation

PHT Corporation is the industry's only dedicated full-service ePRO provider. PHT offers clients a comprehensive solution for acquiring, managing and analyzing data collected directly from patients through all phases of clinical development. More than 115 biopharmaceutical companies use PHT's ePRO System to easily collect high quality, regulatory compliant clinical trial data. PHT's proven LogPad®, NetPRO and versatile SitePad® Systems deliver the voice of the patient, in 88 languages, from homes and sites in 65 countries around the world. Patient experiences captured firsthand by PHT's ePRO System have been used successfully in at least 18 regulatory submissions and 16 approvals to date resulting in 14 PRO-based label claims for sponsors. For more information on PRO and ePRO innovations, review the interactive content and demonstrations at the award-winning www.phtcorp.com.

PHT, LogPad, NetPRO and SitePad are registered trademarks of PHT Corporation.



CONTACT:

For PHT Corporation
Brenda Nashawaty, 617-688-3253
[email protected]

KEYWORDS:   United States  Europe  North America  Massachusetts  Switzerland

INDUSTRY KEYWORDS:   Technology  Consumer Electronics  Data Management  Networks  Software  Practice Management  Health  Biotechnology  Clinical Trials  Pharmaceutical  Mobile/Wireless

MEDIA:

Logo
 Logo

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.